[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"China National Center for Cardiovascular Diseases\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":674},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,99,0,25,[9,48,84,113,134,164,199,228,259,294,319,344,369,399,425,456,481,501,519,540,560,579,604,627,649],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645150","micro-axial-flow-pump-supported-pci-in-complex-coronary-artery-disease-with-ischemic-lv-dysfunction-100645150",false,"NCT07678021","Micro-axial Flow Pump-Supported PCI in Complex Coronary Artery Disease With Ischemic LV Dysfunction","Micro-axial Flow Pump-Supported PCI Plus Optimal Medical Therapy Versus Optimal Medical Therapy Alone in Complex Coronary Artery Disease With Ischemic LV Dysfunction: A Prospective, Multicenter, Randomized Controlled Trial","PIVOT","Inclusion Criteria:\n\n1. The subject is aged ≥18 years;\n2. The subject has been diagnosed with chronic or acute coronary syndrome and has a left ventricular ejection fraction \\\u003C35%;\n3. After comprehensive evaluation by the cardiac team, it is considered that the subject may benefit from PCI treatment;\n4. The subject has signed an informed consent form approved by the ethics committee, has good compliance after discharge, and is willing to undergo clinical follow-up.\n5. At least two vascular occlusive lesions (with the diameter of the occluded vessel \\>2.5mm) or unprotected left main coronary artery disease, and meeting one or more complex procedural criteria, or three-vessel disease, and meeting two or more complex procedural criteria;\n\nExclusion Criteria:\n\n1. Received mechanical circulatory assistance devices (including IABP, ECMO, Impella, etc.) before randomization;\n2. Acute myocardial infarction within 7 days or undergoing thrombolytic therapy;\n3. Combined with aortic dissection, pulmonary embolism, or severe pulmonary hypertension;\n4. Patients with cardiogenic shock or hemodynamic instability;\n5. Cardiopulmonary resuscitation was performed before randomization;\n6. Mechanical complications (including ventricular perforation, interventricular septal perforation, mitral valve chordae rupture, etc.) confirmed before randomization and subsequent to acute myocardial infarction;\n7. The mechanical circulatory assist device cannot be implanted or there are contraindications (including but not limited to left ventricular mural thrombus, artificial aortic valve or cardiac contractile device, moderate or severe aortic stenosis, moderate or severe aortic regurgitation, presence of stents in peripheral vascular access, tortuosity, dissection, and other severe vascular lesions that hinder the implantation of the investigational device, aortic aneurysm or severe malformation abnormalities, blood cell fragility or hemolytic blood system diseases, hypertrophic or hypertrophic obstructive cardiomyopathy, etc.);\n8. Severe abnormalities in platelets, with a count below 50×10\\^9\u002FL or above 600×10\\^9\u002FL;\n9. Active visceral hemorrhage or hemorrhagic stroke occurs within 1 month;\n10. Unable to use antiplatelet or anticoagulant drugs;\n11. Has a history of drug allergy and cannot tolerate conventional cardiovascular drug therapy and intraoperative medications;\n12. Severe renal insufficiency, requiring or expected to require long-term dialysis treatment;\n13. Severe active infection, puncture site infection, sepsis, or septicemia;\n14. Life expectancy is less than or equal to 1 year;\n15. Women who are pregnant or breastfeeding;\n16. Severe right heart failure or severe tricuspid regurgitation;\n17. Participation in other clinical trials has not yet reached the primary endpoint;\n18. Other situations that are unforeseen or deemed unsuitable by the researcher's comprehensive judgment.","ALL","18 Years","80 Years",{"count":22,"type":23},452,"ESTIMATED","INTERVENTIONAL",[26],"NA","Based on a multi-center randomized controlled study, this research aims to evaluate the efficacy and safety of interventional therapy supported by the CorVad percutaneous left ventricular assist system (Micro-axial Flow Pump） for patients with complex coronary heart disease (CHD) complicated by ischemic left ventricular systolic dysfunction. Through a prospective, multi-center, open-label 1:1 randomized controlled trial, a total of 452 patients with severe ischemic systolic dysfunction and complex coronary lesions were enrolled. The study compared the 12-month incidence of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) between patients who received interventional therapy supported by the CorVad percutaneous left ventricular assist system in addition to the most appropriate medical therapy and those who only received the most appropriate medical therapy. This was done to test whether the interventional therapy supported by the CorVad percutaneous left ventricular assist system can improve the prognosis of patients with severe ischemic systolic dysfunction and complex coronary lesions.",[29],"Coronary Artery Disease (CAD)",[31,32,33,34],"Left ventricular assist system","complex coronary heart disease","left ventricular dysfunction","randomized controlled study","NOT_YET_RECRUITING","2026-06-28",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":23},"2026-08-01",{"date":43,"type":23},"2029-12-31",{"name":45,"class":46},"China National Center for Cardiovascular Diseases","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":24,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100643856","vasopressor-agents-in-pulmonary-hypertension-crisis-100643856","NCT07667829","Vasopressor Agents in Pulmonary Hypertension Crisis","Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring","Inclusion Criteria:\n\n1. Age \\> 18 years old;\n2. Signed informed consent form;\n3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and\u002For chronic thromboembolic pulmonary hypertension (CTEPH);\n4. Presenting with manifestations of pulmonary hypertensive crisis;\n5. Receiving both diagnosis and treatment in-hospital;\n6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment.\n\nExclusion Criteria:\n\n1. At SCAI stage D or stage E ;\n2. Patients who only receive a diagnosis but no treatment in the hospital;\n3. Uncontrolled hyperthyroidism;\n4. Complicated with angle-closure glaucoma;\n5. Hypersensitivity to the study drug;\n6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane;\n7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide);\n8. Pregnancy;\n9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.",{"count":56,"type":23},75,[26],"Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring",[60,61,62],"Pulmonary Arterial Hypertension (PAH)","Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","Hypertension, Pulmonary",[62,64,65,66,67,68,69,70,71,72,73,74],"Cardiovascular Diseases","Vascular Diseases","Dopamine","Norepinephrine","Epinephrine","Haemodynamic Monitoring","Efficacy and Safety","Chronic thromboembolic pulmonary hypertension","Heart Failure","Pulmonary circulation","Pulmonary Arterial Hypertension","2026-06-21",{"date":77,"type":39},"2026-06-25",{"date":79,"type":23},"2026-06",{"date":81,"type":23},"2029-01-31",{"name":45,"class":46},3,{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":24,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":47},"100641370","effect-of-mobile-based-home-cardiac-rehabilitation-on-coronary-plaque-100641370","NCT07660419","Effect of Mobile-Based Home Cardiac Rehabilitation on Coronary Plaque","Effect of Mobile Internet Technology-Based Home Cardiac Rehabilitation on Coronary Artery Plaque in Patients With Mild to Moderate Stenosis","MHCRT","Inclusion Criteria:\n\n* 1.Diagnosis of mild-to-moderate coronary artery stenosis: presence of plaque in any coronary artery causing mild (\\\u003C50%) or moderate (50%-69%) luminal stenosis.\n\n  2.Age between 18 and 70 years. 3.Asymptomatic during exercise or recovery phases of cardiopulmonary assessment, including absence of angina, ST-segment depression, or complex arrhythmias at rest or during exercise.\n\n  4.Normal troponin levels. 5.Provided signed informed consent.\n\nExclusion Criteria:\n\n* 1\\. Severe coronary artery stenosis. 2.Presence of severe respiratory or cardiovascular diseases (e.g., acute myocardial infarction, acute tachyarrhythmia, pulmonary edema, severe aortic stenosis).\n\n  3.Angina symptoms or signs during low-intensity exercise (\\\u003C5 METs) or recovery. 4.Complex arrhythmias at rest or during exercise. 5.Hemodynamic abnormalities during exercise (e.g., failure of systolic blood pressure or heart rate to increase, or a decrease in blood pressure with increased exercise workload).\n\n  6.Severe psychological disorders. 7.Left ventricular ejection fraction (LVEF) \\\u003C 40%. 8.Elevated troponin levels. 9.Inability to undergo cardiopulmonary exercise testing due to neuromuscular or musculoskeletal disorders.\n\n  10.Presence of other severe comorbidities. 11.Refusal to sign informed consent.","70 Years",{"count":94,"type":23},176,[26],"This single-center, randomized controlled trial aims to evaluate the efficacy of a mobile internet-based, home-based cardiac rehabilitation program in patients with mild to moderate coronary artery stenosis. A total of 176 eligible participants will be randomized to receive either a personalized lifestyle intervention via a mobile platform or routine clinical care. The primary endpoint is the change in non-calcified coronary plaque volume, as measured by coronary computed tomography angiography (CTA) at 12 months. Participants will be followed for a total of 36 months to comprehensively assess the long-term impact of this digital lifestyle intervention on plaque progression and cardiovascular outcomes.",[29,98],"Coronary Stenosis",[29,100,101,98,102,103],"Home-based Cardiac Rehabilitation","Mobile Health (mHealth)","Non-calcified Plaque","Coronary Computed Tomography Angiography (CCTA)","RECRUITING","2026-06-16",{"date":107,"type":39},"2026-06-22",{"date":109,"type":39},"2024-12-31",{"date":111,"type":23},"2027-12-31",{"name":45,"class":46},{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":121,"targetDuration":4,"studyType":24,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":47},"100642887","unipolar-voltage-mapping-for-personalized-atrial-fibrillation-ablation-100642887","NCT07630857","Unipolar Voltage Mapping for Personalized Atrial Fibrillation Ablation","Unipolar Mapping for Personalized Atrial Fibrillation Ablation: An Interventional Study on Arrhythmia Maintenance and Atrial Remodeling","UNIQS-AF","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years\n* Documented diagnosis of atrial fibrillation (paroxysmal or persistent)\n* Planned to undergo catheter ablation for AF (including patients with recurrent AF after prior ablation)\n* Able and willing to provide written informed consent\n* Able to complete scheduled follow-up visits (3 months post-ablation)\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction \\\u003C 35%\n* Severe valvular heart disease (moderate to severe mitral stenosis or regurgitation)\n* History of intracardiac thrombus\n* Contraindication to anticoagulation\n* Active infection or sepsis\n* Pregnancy or breastfeeding\n* Life expectancy \\\u003C 12 months due to comorbid conditions\n* Participation in another interventional clinical trial within 30 days prior to enrollment",{"count":122,"type":23},200,[26],"Atrial fibrillation (AF) is a common heart rhythm disorder. While catheter ablation is an effective treatment, many patients still experience AF recurrence after the procedure. One major reason is that the mechanisms that maintain AF are not fully understood. Research suggests that the outer layer of the heart (epicardium) may play an important role in keeping AF going. However, current mapping techniques have limitations in detecting electrical signals from both the inner and outer heart layers.\n\nThis study uses a different technique called unipolar voltage mapping, which may more accurately capture electrical signals from both heart layers. Specifically, we focus on a specific type of electrical signal called \"QS potential\" on unipolar mapping, which reflects breakthrough sites between the inner and outer heart layers.\n\nIn this interventional study, participants with AF undergoing catheter ablation will receive personalized ablation guided by unipolar QS-potential mapping. We aim to:\n\nExplore the relationship between unipolar QS-potentials and AF maintenance and atrial remodeling Evaluate the effectiveness of QS-potential guided personalized AF ablation",[126],"Atrial Fibrillation (AF)","2026-06-15",{"date":105,"type":39},{"date":130,"type":23},"2026-06-20",{"date":132,"type":23},"2026-12-20",{"name":45,"class":46},{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":24,"phases":143,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":47},"100641299","phase-4-effect-of-mazdutide-on-coronary-plaque-in-patients-with-coronary-atherosclerosis-and-overweight-or-obesity-100641299","NCT07657676","Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity","Effect of Mazdutide on Coronary Plaque Progression in Patients With Coronary Atherosclerosis and Overweight or Obesity: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. BMI ≥ 28 kg\u002Fm2 or BMI≥ 24kg\u002Fm2 with at least one of the following conditions: dyslipidemia, metabolic associated fatty liver disease, hypertension, prediabetes, type 2 diabetes mellitus, or obesity-related obstructive sleep apnea syndrome (at screening or within 6 months prior to screening).\n3. Coronary stenosis 30-70% confirmed by CAG or CCTA\n4. Signed informed consent\n5. Willing to comply with follow-up\n\nExclusion Criteria:\n\n1. History or evidence of the following :\n\n   1. A history of severe hypoglycemia, or recurrent symptomatic hypoglycemia (≥2 episodes) within the past six months\n   2. Severe heart disease as determined by the investigator, including coronary artery disease that has undergone or is planned for coronary artery bypass grafting or percutaneous coronary intervention, valvular heart disease requiring valve repair or replacement, heart transplantation, severe heart failure (NYHA III-IV) or cardiogenic shock, or a known history of left ventricular ejection fraction ≤30%\n   3. A hemorrhagic\u002Fischemic stroke or transient ischemic attack within six months prior to screening\n   4. A history of acute or chronic pancreatitis, gallbladder\u002Fbile duct disease, or pancreatic injury\n   5. Presence of severe diseases such as malignant tumors, lymphoma, liver cirrhosis, HIV-positive status, etc., with an expected survival of less than 2 years\n   6. Contraindications to GLP-1\u002FGCG dual receptor agonists, such as hypersensitivity or severe intolerance\n   7. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\n2. Use of the following medications or treatments prior to screening :\n\n   1. Use of weight-affecting medications (e.g., systemic steroids, tricyclic antidepressants, psychiatric\u002Fsedative medications, etc.) within three months prior to screening\n   2. Use of GLP-1 RA or GIP\u002FGLP-1 RA (exposure to investigational drugs) within three months prior to screening\n   3. Participation in other clinical trials (exposure to investigational drugs) within three months prior to screening\n   4. Known clinically significant abnormal gastric emptying or current use of medications that directly affect gastrointestinal motility\n3. Laboratory test results meeting any of the following criteria at screening (repeat testing within one week is permitted if there is a clear reason, and the reason for retesting must be documented by the investigator)\n\n   1. Serum calcitonin ≥50 ng\u002FL (pg\u002FmL)\n   2. ALT\u002FAST \\>3.0 × ULN\n   3. eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²\n   4. Abnormal thyroid function (TSH \\>6 mIU\u002FL or \\\u003C0.4 mIU\u002FL)\n4. Pregnancy, planned pregnancy, or breastfeeding\n5. Contraindications to CCTA, including severe allergy to iodine contrast agents, presence of cardiac implantable electronic devices or other metal implants that may affect image analysis\n6. Inability to complete the study or comply with study requirements as determined by the investigator Exclusion criteria for the PET-CT substudy: All exclusion criteria of the main study, as well as contraindications to PET-CT examination",{"count":142,"type":23},116,[144],"PHASE4","This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1\u002FGCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography (CCTA) in patients with coronary atherosclerosis and overweight or obesity. The primary endpoint is the change in total non-calcified plaque volume (NCPV) from baseline to week 52. Secondary endpoints include changes in pericoronary adipose tissue inflammation (fat attenuation index, FAI), plaque composition, metabolic parameters, inflammatory biomarkers, and clinical outcomes. A substudy will include 18F-NAF PET\u002FCT imaging.",[147,148],"Obesity & Overweight","Coronary Heart Disease",[150,151,152,153,154,155,148],"GLP-1RA","CCTA","Mazdutide","Obesity","Plaque","Overweight","2026-06-14",{"date":158,"type":39},"2026-06-18",{"date":160,"type":23},"2026-05-25",{"date":162,"type":23},"2028-02-28",{"name":45,"class":46},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":24,"phases":174,"briefSummary":175,"conditions":176,"keywords":189,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":197,"leadSponsor":198,"locationsCount":4},"100642101","phase-4-study-of-aspirin-removal-in-patients-supported-by-the-fully-magnetically-levitated-ch-vad-pump-100642101","NCT07644247","STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump","A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump (STAR Trial)","STAR","Inclusion Criteria:\n\n\\-\n\nStudy participants must meet all the following criteria:\n\n1. Age ≥18 years old;\n2. Implanted with the CH-VAD pump for advanced heart failure, and the CH-VAD pump is the first implanted left ventricular assist device;\n3. Able to understand the study purpose, voluntarily participate and sign the informed consent form, and willing to comply with the study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n\\-\n\nStudy participants meet any of the following criteria will be excluded:\n\n1. Requirement for additional temporary or permanent mechanical circulatory support after LVAD implantation;\n2. Requirement for physician-mandated antiplatelet therapy after implantation due to medical history, surgical history, concomitant surgical procedures, or other conditions, including mandated presence or absence of antiplatelet agent;\n3. Occurrence of primary endpoint events prior to randomization (within 2-7 days after implantation);\n4. Inability to take oral medications post-implant through 7 days;\n5. Known allergy to aspirin;\n6. Participation in another clinical investigation that may affect study outcome;\n7. Presence of other comorbid conditions, social or psychological conditions, or other conditions, in the investigator's opinion, that may affect participation in the study or compliance with follow-up requirements.",{"count":173,"type":23},370,[144],"This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to the standard antithrombotic regimen of vitamin K antagonist combined with aspirin in terms of safety and efficacy.",[177,178,179,180,181,182,183,184,185,186,187,188],"LVAD (Left Ventricular Assist Device) Thrombosis","LVAD","LVAD (Left Ventricular Assist Device)","LVAD-related GI Bleed","Bleeding","Thrombosis","Stroke","Hemocompatibility-related Adverse Event","Ventricular Assist Device","Aspirin","Antiplatelet Therapy","Antithrombotic Therapy",[190,178,183,181,182,191,186,192],"Left ventricular assist device","Hemocompatibility","Antiplatelet","2026-06-08",{"date":195,"type":39},"2026-06-12",{"date":77,"type":23},{"date":43,"type":23},{"name":45,"class":46},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":24,"phases":209,"briefSummary":210,"conditions":211,"keywords":214,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":227,"locationsCount":47},"100642807","qfr-guided-virtual-stenting-for-preprocedural-physiological-optimization-of-percutaneous-coronary-intervention-a-randomized-controlled-trial-100642807","NCT07635407","QFR-Guided Virtual Stenting for Preprocedural Physiological Optimization of Percutaneous Coronary Intervention: A Randomized Controlled Trial","A Multicenter, Prospective, Randomized Controlled Trial of Preprocedural Physiological Optimization of Percutaneous Coronary Intervention Using Coronary Imaging-Physiology Fusion-Based Virtual Stenting Technology","FAVOR-Virtual","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosis of coronary artery disease requiring percutaneous coronary intervention (PCI) according to current clinical practice.\n* Presence of at least one target coronary lesion considered suitable for PCI and evaluable by angiography-derived Quantitative Flow Ratio (QFR).\n* Ability to undergo coronary angiography and PCI. Provision of written informed consent before study participation.\n\nExclusion Criteria:\n\n* Contraindications to PCI or inability to undergo coronary intervention. Severe renal dysfunction or other conditions making angiographic procedures unsuitable.\n* High bleeding risk judged by investigators.\n* Inability to complete follow-up or comply with study procedures.\n* Life expectancy less than 1 year due to non-cardiovascular comorbidities.\n* Participation in another interventional clinical trial that may interfere with study outcomes.\n* Coronary anatomy unsuitable for QFR-based virtual stenting analysis.\n* Any condition judged by investigators to make study participation inappropriate.",{"count":208,"type":23},1472,[26],"Coronary angiography-guided percutaneous coronary intervention (PCI) remains the standard treatment strategy for patients with coronary artery disease; however, suboptimal post-PCI physiological outcomes remain common and are associated with adverse cardiovascular prognosis. Quantitative Flow Ratio (QFR)-based virtual stenting technology enables simulation of post-intervention coronary physiology before PCI and may facilitate individualized optimization of stent implantation strategies.\n\nThis multicenter, prospective, randomized controlled trial aims to evaluate whether preprocedural physiological optimization of PCI using coronary imaging-physiology fusion-based virtual stenting technology improves clinical outcomes compared with conventional angiography-guided PCI. Eligible patients undergoing PCI for coronary artery disease will be randomized in a 1:1 ratio to either virtual stenting-guided PCI optimization or standard angiography-guided PCI.\n\nThe primary endpoint is major adverse cardiovascular events (MACE), defined as a composite of all-cause death, nonfatal myocardial infarction, and ischemia-driven repeat revascularization within 1 year after PCI. Secondary endpoints include post-PCI physiological optimization, cardiovascular death or nonfatal myocardial infarction, repeat revascularization, quality of life, procedural safety, and health economic outcomes.",[212,98,213],"Coronary Artery Disease","Ischemic Heart Disease",[215,216,217,218,212,219,220],"Percutaneous Coronary Intervention","Quantitative Flow Ratio","Virtual Stenting","Coronary Physiology","Physiological Optimization","Functional Revascularization","2026-06-07",{"date":223,"type":39},"2026-06-09",{"date":38,"type":23},{"date":226,"type":23},"2028-12-31",{"name":45,"class":46},{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":24,"phases":238,"briefSummary":240,"conditions":241,"keywords":242,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":257,"locationsCount":258},"100563394","early-phase-1-discontinuation-of-anticoagulations-after-successful-catheter-ablation-of-atrial-fibrillation-100563394","NCT06615596","Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation: DESTINATION Study","DESTINATION","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosed paroxysmal, persistent, or longstanding persistent AF\n* Successful procedure (defined as restoration of sinus rhythm after PV isolation for paroxysmal AF, restoration of sinus rhythm after PV isolation and completion of additional ablation for persistent AF, according to 2017 HRS\u002FEHRA\u002FECAS\u002FAPHRS\u002FSOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation) and no recurrence within 3 months of ablation, using a cooled tip RF-, laser- or cryo-balloon-catheter\n* No periprocedural complications\n* Signed informed consent\n* Male with CHA2DS2-VASC score ≥1, female with score ≥2.\n\nExclusion Criteria:\n\n* Valvular AF (moderate- severe mitral insufficiency; relevant mitral stenosis with a mean pressure gradient \\>5mmHg)\n* Reversible AF (e.g. uncontrolled hyperthyroidism)\n* Prior AF ablation (including surgical ablation)\n* History of left atrial appendage occlusion\u002Fligation\u002Fexcision\n* Concomitant surgical ablation\n* Left atrial diameter \\>50 mm\n* Left atrial or LAA thrombus\n* Pregnancy\u002Fbreast feeding\n* Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study\n* Patient has a non-arrhythmic condition necessitating long-term oral anticoagulation (i.e. PE, ventricular thrombus, peripheral thrombosis, etc)\n* Recent myocardial infarction, NYHA class IV heart failure, patent foramen ovale, recent trauma or other prothrombotic conditions\n* Patient with special risk factors for stroke unrelated to AF, specifically known thrombophilia\u002F hypercoagulability, uncontrolled hypertension (systolic blood pressure \\>180 mmHg and\u002For diastolic blood pressure \\>100 mmHg within 4 days of enrollment), untreated familial hyperlipidemia, known vascular anomaly (intracranial aneurysm\u002F arteriovenous malformation or chronic vascular dissection), or known severe carotid disease.\n* Patient has bleeding contra-indication to oral anticoagulation (such as bleeding diathesis, hemorrhagic disorder, significant gastrointestinal bleeding within 6 months, intracranial\u002Fintraocular\u002F atraumatic bleeding history, fibrinolysis within 48 hours of enrollment).\n* Patient has other contraindication to oral anticoagulation or treatment with antiplatelet agent\n* Patient has been on strong CYP3A inducers (such as rifampicin, phenytoin, phenobarbital, or carbamazepine) or strong CYP3A inhibitors (such as ketoconazole or protease inhibitors) within 4 days of enrolment\n* Structural congenital heart disease\n* Recent stroke or intracranial hemorrhage within 6 months\n* Inability to adequately understand nature, significance, implications and risks of study precipitation and to comply with follow-up (i.e. bipolar disorders, severe depression, suicidal tendencies, among others) as judged by the local physician, ongoing drug or alcohol addiction (\\> 8 drinks\u002Fweek)\n* Patients who are \\> 85 years of age\n* Patients who are critically ill or who have a life expectancy \\<3 years\n* Patient is unable or unwilling to provide informed consent\n* Patient is included in another randomized clinical trial or a clinical trial requiring an insurance",{"count":237,"type":23},3160,[239],"EARLY_PHASE1","The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF). Current guidelines recommend continued anticoagulation based on stroke risk scores, even post-ablation, potentially exposing patients to unnecessary bleeding risks. This international, multicenter, randomized controlled trial aims to compare thromboembolic and bleeding event risks between patients who continue and discontinue anticoagulation after ablation. The study involves 3,160 AF patients, all free of AF recurrence within 6 months to 1 year after ablation. Smart wearable monitors will track recurrence, and patients are followed for 24 months to assess event rates. Findings may reshape anticoagulation guidelines, improving clinical practice for AF patients worldwide.",[126],[243,244,245,246,247,248,249,250],"Atrial Fibrillation","Catheter Ablation","Anticoagulation Discontinuation","Post-Ablation Monitoring","Randomized Controlled Trial","Thromboembolic Risk","Smart Wearable Devices","AF Recurrence Detection","2026-06-02",{"date":253,"type":39},"2026-06-04",{"date":255,"type":39},"2025-08-05",{"date":43,"type":23},{"name":45,"class":46},12,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":24,"phases":269,"briefSummary":270,"conditions":271,"keywords":275,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":47},"100640008","phase-4-rhbnp-for-prevention-of-cardiac-surgery-associated-acute-kidney-injury-csa-aki-100640008","NCT07617675","rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)","Perioperative Recombinant Human Brain Natriuretic Peptide for Renal Protection in Cardiac Surgery: the PROTECT-CS Randomized Clinical Trial","PROTECT-CS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Scheduled (elective) cardiac surgery requiring cardiopulmonary bypass\n* Presence of at least one of the following AKI risk factors:\n* Age ≥ 70 years\n* Preoperative renal impairment (eGFR ≤ 60 mL\u002Fmin\u002F1.73 m² or urine protein ≥ +2 at screening)\n* Type 2 diabetes mellitus\n* Heart failure, defined as NYHA Class II-IV with NT-proBNP ≥ 125 pg\u002FmL at screening; for participants with atrial fibrillation, NT-proBNP ≥ 365 pg\u002FmL is required\n* Able to understand and provide written informed consent, and willing and able to comply with all study protocol requirements\n\nExclusion Criteria:\n\n* Cardiogenic shock\n* Severe hypotension (systolic blood pressure ≤ 90 mmHg) at screening\n* Restrictive or obstructive cardiomyopathy, pericarditis, or cardiac tamponade\n* Preoperative chronic kidney disease stage 4 or higher (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²), or renal instability as judged by the investigator\n* Known AKI diagnosed per KDIGO criteria within 48 hours prior to surgery\n* Receipt of any form of renal replacement therapy within 30 days prior to surgery\n* Use of ventricular assist device, intra-aortic balloon pump, or any other mechanical cardiac support device within 7 days prior to surgery\n* Chronic hepatic insufficiency (Child-Pugh Class B or C) or hepatic dysfunction (ALT or AST \\> 2× upper limit of normal \\[ULN\\], or total bilirubin \\> 1.5× ULN)\n* Active hepatitis B (HBsAg positive with HBV-DNA indicating active viral replication), active hepatitis C (HCV antibody positive with HCV-RNA indicating active viral replication), positive syphilis screen, known HIV infection, or positive HIV test\n* Confirmed or treated endocarditis, sepsis, or active infection requiring antibiotic treatment within 30 days prior to surgery\n* Requirement for aortic dissection repair, complex congenital heart surgery, emergency surgery, or life-saving surgery\n* History of malignant tumor, solid tumor, metastatic tumor, or hematological malignancy within the past 5 years\n* Prior organ transplantation or current use of immunosuppressive agents\n* Any condition that may conflict with or contraindicate the use of intravenous vasodilator therapy\n* Prior adverse reaction to nesiritide (recombinant BNP)\n* Participation in any other clinical trial within 30 days prior to surgery\n* Pregnant or breastfeeding women\n* Any other condition that, in the judgment of the investigator, renders the participant unsuitable for study participation",{"count":268,"type":23},694,[144],"Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common and serious perioperative complication, independently associated with prolonged hospitalization, increased mortality, and progression to chronic kidney disease. Despite advances in surgical techniques and postoperative care, no widely accepted pharmacological prevention strategy exists.\n\nRecombinant human brain natriuretic peptide (rhBNP) exerts vasodilatory, diuretic, and natriuretic effects, reduces cardiac preload and afterload, and has demonstrated safety and efficacy in treating congestive heart failure. Preliminary studies suggest rhBNP may reduce postoperative serum creatinine, increase urine output, and improve renal outcomes; however, large-scale randomized controlled evidence is lacking.\n\nThe PROTECT-CS trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of perioperative continuous intravenous rhBNP infusion (0.01 μg\u002Fkg\u002Fmin for 48 ± 2 hours) for prevention of AKI in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. A total of 694 participants will be enrolled across 7 centers in China.",[272,273,274],"AKI - Acute Kidney Injury","Cardiac Surgical Procedures","Cardiopulmonary Bypass",[276,277,278,279,280,281,282,283,284,285],"Recombinant human brain natriuretic peptide","rhBNP","Nesiritide","Acute kidney injury","Cardiac surgery","Cardiopulmonary bypass","Renal protection","Randomized controlled trial","Cardiac surgery-associated acute kidney injury","CSA-AKI","2026-05-29",{"date":288,"type":39},"2026-06-01",{"date":290,"type":23},"2026-05-01",{"date":292,"type":23},"2029-07-31",{"name":45,"class":46},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":24,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":47},"100639560","pulsed-field-ablation-outcomes-with-efficacy-and-randomization-in-atrial-fibrillation-power-af-100639560","NCT07601763","Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)","Pulsed Field Ablation for Atrial Fibrillation Including Posterior Wall and Linear Ablation: A Randomized Controlled Trial of Safety and Efficacy (POWER-AF)","POWER-AF","Inclusion Criteria:\n\n1. Atrial fibrillation patients who will accept catheter ablation.\n2. Age ≥ 18.\n3. Be capable of understanding and signing the informed consent form.\n\nExclusion Criteria:\n\n1. Have contraindications for catheter ablation (such as atrial thrombosis, decompensated heart failure, etc.)\n2. Have accepted catheter ablation before.\n3. Myocardial infarction, or any cardiac interventional\u002Fsurgery has been performed within 3 months.\n4. Had a stroke or transient ischemic attack within 6 months.\n5. Allergy to iodine contrast agents.\n6. Participate in clinical trials related to other drugs or devices.\n7. Pregnant women, lactating women, or women with plans to become pregnant shortly.\n8. Active stage of infection.\n9. Secondary atrial fibrillation, such as combined with rheumatic heart disease, hypertrophic cardiomyopathy, etc.\n10. Patients who do not agree to be enrolled or are unable to cooperate to complete the study",{"count":303,"type":23},1574,[26],"Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice. As of 2019, there were approximately 59.7 million patients with AF worldwide, including atrial flutter (AF). Atrial fibrillation can significantly increase the risks of stroke, thromboembolism and heart failure in patients, seriously affecting their quality of life.\n\nCatheter ablation is the main means for rhythm control in patients with atrial fibrillation. A large number of clinical studies have confirmed the effectiveness and safety of catheter ablation for atrial fibrillation. It is significantly superior to drug treatment in maintaining sinus rhythm and can significantly improve symptoms and quality of life.\n\nPulsed electric field ablation (PFA) is a novel ablation method that utilizes pulsed electric fields as energy. It uses multiple short-duration and high-voltage electrical pulses to release ablation energy, selectively causing myocardial cells to rupture and die. However, it has no obvious damaging effect on blood vessels, nerves, and tissues around the heart, such as the lungs, esophagus, and phrenic nerve.\n\nThis trial was designed based on the advantage of the characteristic that PFA does not damage the esophagus, confining the damage to the posterior half of the left atrium and the circumferential isthmus of the mitral valve. While improving the ablation success rate, it is possible to protect the function of the left atrium. This study aims to verify the superiority of the new rhythm control strategy in a large-scale population by launching a prospective randomized controlled trial.",[126,307,308,309,310],"Atrial Fibrillation Ablation","Atrial Fibrillation Recurrent","Pulsed Field Ablation","Radiofrequency Catheter Ablation","2026-05-24",{"date":313,"type":39},"2026-05-28",{"date":315,"type":39},"2025-04-16",{"date":317,"type":23},"2028-11-30",{"name":45,"class":46},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":327,"targetDuration":4,"studyType":24,"phases":329,"briefSummary":330,"conditions":331,"keywords":332,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":341,"leadSponsor":343,"locationsCount":4},"100636943","a-study-of-using-carto-sound-fam-to-guide-pulsed-field-ablation-for-atrial-fibrillation-100636943","NCT07572253","A Study of Using CARTO SOUND™ FAM to Guide Pulsed Field Ablation for Atrial Fibrillation","An Exploratory Study on Pulmonary Vein Pulsed Field Ablation Guided by CARTO SOUND™ FAM","CSPFA","Inclusion Criteria:\n\n* Diagnosis of paroxysmal atrial fibrillation with an indication for catheter ablation.\n* Willing and able to provide written informed consent.\n* Age between 18 and 80 years (inclusive).\n* Able and willing to comply with all pre-procedure, post-procedure, and follow-up visits and assessments.\n\nExclusion Criteria:\n\n* Valvular atrial fibrillation, untreated or uncontrolled thyroid disease, acute coronary syndrome, or atrial fibrillation secondary to cardiomyopathy.\n* Any contraindication to catheter ablation (e.g., left atrial thrombus, coagulopathy preventing anticoagulation, severe hepatic\u002Frenal dysfunction, psychiatric illness).\n* Pregnancy or breastfeeding.\n* Malignancy, cachexia, severe ascites, body mass index (BMI) \\> 40 kg\u002Fm², or severe sleep apnea syndrome.\n* Participation in another clinical study.\n* Any other condition that the investigator considers inappropriate for study participation.\n* Contraindication to any study device as specified in the respective instructions for use (IFU).",{"count":328,"type":23},70,[26],"This study is being done to see if a new method for treating a heart rhythm problem called paroxysmal atrial fibrillation (AFib) is safe and works well. AFib causes the upper chambers of the heart (the atria) to beat irregularly, which can lead to symptoms like palpitations, shortness of breath, and tiredness. The usual treatment for AFib when medicines do not help is a procedure called catheter ablation. This procedure uses heat or cold to create small scars in the heart to block abnormal electrical signals. This study uses a newer energy source called pulsed field ablation (PFA), which may be safer for the surrounding tissues (like the esophagus and nerves) because it mainly affects heart cells. Another special part of this study is how doctors build a 3D picture of the left atrium - the part of the heart where AFib starts. Instead of the standard method, the investigators will use a technology called CARTO SOUND™ FAM. This combines heart ultrasound (ICE) with a mapping system to quickly create an accurate 3D model of the left atrium without needing a CT scan or extra injections of dye. The main questions are: Can the doctor successfully isolate all four pulmonary veins (the areas where AFib often starts) using only the study devices (CARTO SOUND™ FAM and PFA)? What are the side effects and safety of this new combination within 30 days after the procedure? About 70 adults aged 18 to 80 with paroxysmal AFib will take part. Participants will have one ablation procedure and will be followed for 1 month after the procedure. The study will measure how long the procedure takes, how much X-ray is used, how well the catheter touches the heart tissue, and any serious medical events. This is an early (feasibility) study to gather information for future, larger studies. It is sponsored by Fuwai Hospital, Chinese Academy of Medical Sciences, and will be done in three hospitals in China.",[243],[309,333,334,335,336],"Pulmonary Vein Isolation","CARTO SOUND FAM","Intracardiac Echocardiography","Feasibility Study","2026-05-14",{"date":339,"type":39},"2026-05-18",{"date":288,"type":23},{"date":342,"type":23},"2027-08-30",{"name":45,"class":46},{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":352,"targetDuration":4,"studyType":24,"phases":354,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":47},"100639948","phase-4-effect-of-finerenone-on-myocardial-fibrosis-and-cardiac-function-in-hfmrefhfpef-patients-100639948","NCT07583173","Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF\u002FHFpEF Patients","A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Finerenone on Myocardial Fibrosis and Cardiac Structure and Function in Heart Failure Patients With Mildly Reduced or Preserved Ejection Fraction","FINE-FOCUS","Inclusion Criteria:\n\n1. Aged 18 to 80 years (inclusive), any gender.\n2. Symptomatic heart failure (NYHA class II-IV).\n3. Emergency department visit or hospitalization for HF within the past 3 months, or escalation of intravenous or oral diuretic therapy for worsening HF within the past 3 months.\n4. LVEF ≥40% measured by echocardiography or CMR within the past 30 days prior to screening.\n5. NT-proBNP ≥300 pg\u002FmL for patients in sinus rhythm; NT-proBNP ≥900 pg\u002FmL for patients with atrial fibrillation.\n6. Presence of myocardial fibrosis, defined as ECV ≥27% measured by CMR at baseline.\n7. Capable of providing voluntary written informed consent.\n\nExclusion Criteria:\n\n* 1\\. eGFR \\\u003C25 mL\u002Fmin\u002F1.73 m² at screening or enrollment. 2. Serum potassium concentration ≥5.0 mmol\u002FL at screening or enrollment. 3. Prior confirmed diagnosis of HFrEF. 4. Acute inflammatory heart disease (e.g., acute myocarditis). 5. Acute myocardial infarction or other event likely to have reduced LVEF within 30 days prior to randomization.\n\n  6\\. Coronary artery bypass grafting within 30 days prior to randomization. 7. Percutaneous coronary intervention within 30 days prior to randomization. 8. History of stroke or transient ischemic attack (TIA) within 90 days prior to randomization.\n\n  9\\. Conditions where the investigator considers the primary cause of dyspnea (and thus heart failure symptoms) to be severe pulmonary disease, anemia, or obesity. Specific exclusions include: severe pulmonary disease requiring home oxygen therapy or long-term oral steroids; history of primary pulmonary hypertension; hemoglobin \\\u003C100 g\u002FL; severe valvular heart disease; BMI ≥50 kg\u002Fm².\n\n  10\\. Systolic blood pressure (SBP) \\>160 mmHg despite combination therapy with 3 antihypertensive drugs, OR SBP \\>180 mmHg on any treatment measured on (two consecutive occasions at least 2 minutes apart).\n\n  11\\. Severe malignant ventricular arrhythmia or atrial fibrillation with resting ventricular rate \\>100 bpm.\n\n  12\\. Symptomatic hypotension with mean SBP \\\u003C90 mmHg. 13. Any HF condition requiring surgical intervention (e.g., severe aortic stenosis or mitral regurgitation).\n\n  14\\. History of peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, primary right ventricular cardiomyopathy, constrictive pericarditis, hereditary hypertrophic cardiomyopathy, or infiltrative cardiomyopathy (including amyloidosis).\n\n  15\\. Contraindications to CMR (e.g., magnetic metal implants, claustrophobia, contrast allergy).\n\n  16\\. History of hyperkalemia or acute renal failure during prior MRA therapy. 17. Known allergy or severe adverse reaction to finerenone. 18. History of severe hepatic impairment (Child-Pugh C). 19. Requirement for any intravenous inotropic drugs or mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device) within 24 hours prior to randomization.\n\n  20\\. Current or prior use (within 4 weeks before screening) of any MRA (e.g., spironolactone, eplerenone, canrenone, esaxerenone).\n\n  21\\. Use of renin inhibitors or potassium-sparing diuretics prior to randomization that cannot be discontinued.\n\n  22\\. Severe comorbidities (e.g., malignancy, lymphoma, cirrhosis, HIV-positive) with life expectancy \\\u003C2 years.\n\n  23\\. Pregnancy, lactation, or planning pregnancy. Women of childbearing potential must have a negative serum pregnancy test pre-treatment, agree to serum\u002Furine pregnancy tests at study visits (Months 3 and 6), and commit to using highly effective contraception during the study and for 3 months after. Male participants with female partners of childbearing potential must also agree to use highly effective contraception during the study and for 3 months after.\n\n  24\\. Participation in another clinical trial within 3 months prior to this study.\n\n  25\\. Any condition, in the investigator's judgment, that would preclude safe study participation or protocol compliance.",{"count":353,"type":23},104,[144],"FINE-FOCUS study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of Finerenone versus placebo on myocardial fibrosis and cardiac structure\u002Ffunction as assessed by cardiac magnetic resonance (CMR) in symptomatic heart failure patients with a left ventricular ejection fraction (LVEF) ≥40%. A sub-study will include 18F-FAPI-PET\u002FCT imaging to evaluate the effect of finerenone on myocardial fibrosis.",[72],[358,359,360,361],"Heart failure with mildly reduced ejection fraction","Heart failure with preserved ejection fraction","Myocardial fibrosis","Imaging","2026-05-06",{"date":364,"type":39},"2026-05-13",{"date":366,"type":23},"2026-05-15",{"date":111,"type":23},{"name":45,"class":46},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":18,"minAge":377,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":24,"phases":380,"briefSummary":381,"conditions":382,"keywords":386,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":47},"100617375","phase-4-echo-guided-vs-fluoroscopy-guided-transcatheter-aortic-valve-replacement-in-patients-with-aortic-stenosisecho-tavr-100617375","NCT07317804","Echo-Guided vs Fluoroscopy-Guided Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis（ECHO-TAVR）","Echo-Guided vs Fluoroscopy-Guided Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis","ECHO-TAVR","Inclusion Criteria:\n\n* 1\\. Patients aged 70 years or older with obvious clinical symptoms or a left ventricular ejection fraction less than 50% due to severe aortic valve stenosis (aortic valve orifice area \\\u003C 1.0 cm² or peak velocity ≥ 4.0 m\u002Fs or mean transvalvular pressure ≥ 40 mmHg); or patients with obvious clinical symptoms of low blood flow and low pressure difference aortic valve stenosis (effective aortic valve orifice area \\\u003C 1.0 cm², mean transvalvular pressure difference \\\u003C 40 mmHg, left ventricular ejection fraction \\\u003C 50%, stroke volume index \\\u003C 35 ml\u002Fm², and diagnosed as true severe aortic valve stenosis by dobutamine stress test);\n* 2\\. Patients aged 65 years ≤ age \\\u003C 70 years with severe aortic stenosis who have surgical contraindications or high risks, or have other risk factors such as post-chest radiotherapy, liver failure, diffuse severe aortic calcification, extreme weakness, etc., or patients refuse to undergo routine open-chest surgery;\n* 3\\. The patient's anatomical structure is suitable for TAVR and can tolerate transesophageal ultrasound;\n* 4\\. The patient has signed the informed consent form and is willing to participate in this study.\n\nExclusion Criteria:\n\n* 1\\. Imaging (ultrasound and\u002For CT and\u002For MRI) confirmed a lesion, thrombus or calculus in the left ventricle;\n* 2\\. Severe obstruction of the left ventricular outflow tract;\n* 3\\. Severe right ventricular dysfunction;\n* 4\\. Acute myocardial infarction within 30 days before the procedure;\n* 5\\. Active endocarditis history within 180 days before the procedure;\n* 6\\. Inappropriate aortic root anatomy (such as combined aortic dissection, excessive aortic annulus, risk of coronary artery occlusion, etc.);\n* 7\\. Severe calcification and distortion of the surgical approach;\n* 8\\. Left ventricular ejection fraction less than 20%;\n* 9\\. Other cardiac diseases that require concurrent treatment (such as severe mitral regurgitation, atrial fibrillation, etc.);\n* 10\\. History of stroke or transient ischemic attack within 90 days before the procedure;\n* 11\\. Liver cirrhosis or active liver disease;\n* 12\\. Renal insufficiency (creatinine clearance rate \\\u003C 30 mL\u002Fmin) and\u002For undergoing renal replacement therapy;\n* 13\\. Unable to tolerate anticoagulation therapy during or after the procedure;\n* 14\\. Participating in other drug or device research;\n* 15\\. Any emergency or surgical operation within 30 days before the procedure;\n* 16\\. Other severe comorbidities, even if the valve stenosis is corrected, the expected life expectancy is less than 1 year;\n* 17\\. Other conditions deemed unsuitable for TAVR surgery by the cardiac team.","65 Years",{"count":379,"type":23},212,[144],"Aortic stenosis (AS) is a common valvular heart disease whose prevalence increases markedly with age-approximately 2-4% in individuals aged 65 years and older, and up to 3.4% for severe AS in those over 75. Degenerative calcific AS predominates in high-income countries, whereas rheumatic disease remains a major cause in low-income regions. With global population aging, the disease burden of AS continues to rise.\n\nTranscatheter aortic valve replacement (TAVR\u002FTAVI), owing to its minimally invasive nature, has become an important treatment option for severe AS and selected aortic regurgitation patients, expanding from high-surgical-risk populations to those at intermediate and low risk. In recent years, the number of TAVR procedures in many regions has surpassed or approached that of surgical aortic valve replacement, and major clinical guidelines have elevated TAVR to a recommended standard therapy.\n\nConventional TAVR relies on combined fluoroscopic and echocardiographic guidance. However, perioperative complications remain frequent in elderly and high-risk patients, particularly acute kidney injury (AKI), which significantly increases short- and long-term mortality. Contrast exposure during the procedure is a major contributor to AKI; thus, clinical practice increasingly favors strategies that minimize contrast use, such as low-dose and low-kV imaging. Elevated contrast concentration in the renal tubules increases viscosity, prolongs renal exposure, and can lead to tubular injury and renal dysfunction. Continuous radiation exposure during vascular access, device positioning, valve deployment, and post-release assessment also poses safety concerns for both patients and medical staff.\n\nEchocardiography-only guidance for TAVR has therefore emerged as an attractive alternative, with the potential to replace fluoroscopy and contrast for anatomical visualization and device positioning, thereby reducing radiation exposure and contrast-related kidney injury. However, no prospective randomized study has directly compared echocardiography-only guidance with conventional fluoroscopy-plus-echocardiography guidance, and current evidence remains preliminary.\n\nTo address this gap, a randomized controlled trial was designed to evaluate whether echocardiography-only guidance is non-inferior to combined fluoroscopic and echocardiographic guidance in terms of device success, while also assessing the safety, efficacy, and clinical feasibility of both approaches.",[383,384,385],"Aortic Stenosis","TAVI","TAVI(Transcatheter Aortic Valve Implantation)",[387,388,385,384,383,389,390],"Ultrasound-guided","Percutaneous Intervention","PAN Procedure","non fluoroscopic","2026-04-16",{"date":393,"type":39},"2026-04-21",{"date":395,"type":23},"2026-04-26",{"date":397,"type":23},"2028-07-31",{"name":45,"class":46},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":406,"targetDuration":408,"studyType":409,"phases":4,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":47},"100633308","a-chinese-multicenter-study-on-surgical-techniques-and-outcomes-across-the-lifespan-in-congenital-heart-disease-100633308","NCT07524998","A Chinese Multicenter Study on Surgical Techniques and Outcomes Across the Lifespan in Congenital Heart Disease","Evaluation of Surgical Techniques and Outcomes Across the Lifespan in Congenital Heart Disease Based on a Chinese Multicenter Database","Inclusion Criteria:\n\n* Clinical diagnosis of Complex Congenital Heart Disease (CCHD) who underwent surgical intervention and were enrolled in the 13th Five-Year Plan National Congenital Heart Disease Surgery Database\n* Clinical diagnosis of CCHD requiring surgical\u002Fintrauterine intervention or cardiac rehabilitation\n* Willing to sign informed consent and complete follow-up\n\nExclusion Criteria:\n\n* Lost to follow-up\n* \\>30% missing core clinical data\n* Severe extracardiac malformations, systemic dysfunction, or other conditions precluding study participation, per sub-study specific exclusion criteria",{"count":407,"type":23},3000,"1 Year","OBSERVATIONAL","The goal of this observational study is to learn about recovery after heart surgery for people with Complex Congenital Heart Disease (CCHD), build a comprehensive data platform for CCHD care across a person's whole life, and create a China-specific quality control system to improve CCHD surgical care.\n\nThe main questions it aims to answer are:\n\nWhat are the main risk factors that affect how well people with CCHD recover after heart surgery? Can a whole life course, multi-dimensional data platform for CCHD care be built to support better clinical quality control? Can a China-specific system to evaluate and control the quality of CCHD heart surgery be developed to guide national health policies and improve patient outcomes?\n\nParticipants in this study are people with CCHD who have had or will have heart surgery at participating medical centers. This includes two groups:\n\nA retrospective group: People who already had CCHD heart surgery and were included in the existing National Congenital Heart Disease Surgery Database.\n\nA prospective group: People who are scheduled to have CCHD heart surgery as part of related sub-studies of this project.\n\nPeople who are lost to follow-up or have more than 30% missing data will not be included.\n\nParticipants will:\n\nFor the retrospective group: Have their past medical records (from surgery and follow-up) analyzed by researchers to find risk factors linked to recovery after CCHD heart surgery.\n\nFor the prospective group: Have their pre-surgery tests, surgery details, care during and after surgery, and follow-up data (including up to 1 year after surgery) collected as part of their regular medical care.\n\nResearchers will combine data from both groups into a new registry, work with a third-party committee to check data quality, and use this combined data to build a quality control and evaluation system for CCHD heart surgery. This system will help show the current state of CCHD care in China and guide national health decisions.",[412,413,414,415,416,417],"Congenital Heart Disease","Complex Congenital Heart Disease","Surgery (Cardiac)","Perioperative Care","Quality Control","Health Care","2026-04-10",{"date":420,"type":39},"2026-04-13",{"date":422,"type":39},"2025-02-01",{"date":81,"type":23},{"name":45,"class":46},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":18,"minAge":432,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":24,"phases":436,"briefSummary":437,"conditions":438,"keywords":444,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":4},"100634103","exercise-targeted-smart-lifestyle-management-100634103","NCT07535333","Exercise-Targeted Smart Lifestyle Management","Study on the Improvement Effects of Intelligent Lifestyle Management, Targeting Exercise Capacity Enhancement, on Overweight\u002FObesity With Metabolic Syndrome","Inclusion Criteria:\n\n* Aged between 20 and 60 years.\n* Overweight or obese, with a Body Mass Index (BMI) ≥ 24 kg\u002Fm² and \\\u003C 40 kg\u002Fm².\n* Patients with impaired metabolic parameters regarding glucose, lipids, and blood pressure，meet at least two of the following criteria:\n\n  * Central obesity: Waist circumference ≥ 90 cm for males or ≥ 85 cm for females.\n  * Hyperglycemia: Fasting plasma glucose (FPG) ≥ 6.1 mmol\u002FL, or 2-hour plasma glucose ≥ 7.8 mmol\u002FL during an oral glucose tolerance test (OGTT), and\u002For currently receiving treatment for previously diagnosed diabetes.\n  * Hypertension: Blood pressure ≥ 130\u002F85 mmHg, and\u002For currently receiving treatment for previously diagnosed hypertension.\n  * Elevated fasting triglycerides (TG): ≥ 1.7 mmol\u002FL.\n  * Reduced fasting high-density lipoprotein cholesterol (HDL-C): \\\u003C 1.04 mmol\u002FL.\n\nExclusion Criteria:\n\n* History of cardiovascular or cerebrovascular disease, or in the acute phase, including: angina pectoris, myocardial infarction, coronary revascularization surgery, stroke (ischemic or hemorrhagic, including transient ischemic attack), symptomatic peripheral artery disease requiring surgery or diagnosed via angiographic techniques, ventricular arrhythmias, uncontrolled atrial fibrillation, congestive heart failure (New York Heart Association class III or IV), hypertrophic cardiomyopathy, history of aneurysm with diameter ≥ 5.5 cm, or history of aneurysm surgery.\n* Malignancy or history of malignancy within the past five years.\n* Religious restrictions or dysphagia preventing adherence to the recommended diet.\n* Contraindications to exercise, such as orthopedic disorders.\n* Participation in other weight-loss programs (\\> 5 kg weight loss) within the six months prior to the screening visit.\n* History of bariatric surgery or intention to undergo bariatric surgery within the next 12 months.\n* History of small or large bowel resection or inflammatory bowel disease.\n* Obesity due to endocrine disorders of unknown cause (excluding treated hypothyroidism).\n* Allergy to any food components of the Mediterranean diet.\n* Immunodeficiency or HIV positive status.\n* Cirrhosis or liver failure.\n* Severe psychiatric disorders, including schizophrenia, bipolar disorder, eating disorders, or depression requiring hospitalization in the past 6 months.\n\nSevere comorbidities with a life expectancy of less than 24 months.\n\n* Alcoholism, addiction, or drug abuse in the past six months (or daily alcohol consumption \\> 50 g).\n* History of major organ transplantation.\n* Concomitant use of immunosuppressive or cytotoxic medications.\n* Current use of systemic corticosteroids.\n* Current use of weight-loss medications.\n* Currently participating in another randomized clinical trial.\n* Patients with acute infection or inflammation (e.g., pneumonia) may -participate 3 months after resolution of the condition.\n* Pregnant or planning to become pregnant during the study period.\n* Any other condition that may interfere with protocol compliance.\n* Refusal to sign the informed consent document.","20 Years","60 Years",{"count":435,"type":23},435,[26],"To investigate the effects of simple dietary management and diet combined with exercise capacity-targeted intelligent lifestyle management on improving metabolic indicators in patients with overweight\u002Fobesity and metabolic syndrome.",[439,440,441,442,443],"M-health","Metabolic Syndrome","Lifestyle Alteration","Lifestyle (Sedentary Behavior and Physical Activity)","Overweight , Obesity",[445,440,446,447,443],"mhealth","Lifestyle (sedentary behavior and physical activity)","Mediterranean Diet","2026-04-09",{"date":450,"type":39},"2026-04-17",{"date":452,"type":23},"2026-05",{"date":454,"type":23},"2027-06",{"name":45,"class":46},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":24,"phases":466,"briefSummary":467,"conditions":468,"keywords":470,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":480},"100616211","aortic-no-touch-vs-partial-aortic-clamping-in-off-pump-cabg-100616211","NCT07302659","Aortic No-Touch vs Partial Aortic Clamping in Off-Pump CABG","Surgical Techniques to Prevent Perioperative Neurologic Complications in Patients Undergoing Coronary Artery Bypass Grafting","PROTECT-CABG","Inclusion Criteria:\n\n* Adult patients (\\>18 years old) with multivessel coronary artery disease who are scheduled to undergo isolated off-pump coronary artery bypass grafting and who provide informed consent to participate in this study.\n\nExclusion Criteria:\n\n* Indications for cardiopulmonary bypass surgery (or no contraindications to on-pump surgery);\n* Great saphenous vein is unsuitable for use as a graft conduit;\n* Subclavian artery stenosis or occlusion, or any contraindication to the use of the internal mammary artery as a graft conduit;\n* History of previous cardiac surgery;\n* Emergency surgery;\n* Inability to apply an aortic clamp due to severe ascending aortic calcification;\n* Expected inability to tolerate MRI or contraindications to MRI (e.g., known intolerance to MRI, an implanted permanent pacemaker, or an anticipated need for permanent pacemaker implantation);\n* Inability to complete neurocognitive assessment due to language barriers or visual\u002Fhearing impairment.",{"count":465,"type":23},380,[26],"To explore surgical strategies that reduce perioperative neurologic complications in cardiovascular surgery, with the aim of improving perioperative outcomes and quality of life while reducing the socioeconomic burden. Specifically:\n\nThis multicenter, randomized controlled clinical trial will evaluate the benefits of a novel aortic no-touch technique in reducing perioperative silent brain infarction(SBI) among patients undergoing surgical treatment for coronary artery disease. The findings are expected to provide a safe and effective myocardial revascularization strategy for individuals at high risk of cerebral ischemia.",[469],"Coronary Artery Bypass Graft (CABG)",[471,472],"coronary artery bypass graft","Silent Brain Infarction",{"date":474,"type":39},"2026-04-14",{"date":476,"type":39},"2026-03-10",{"date":478,"type":23},"2028-06-30",{"name":45,"class":46},4,{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":488,"targetDuration":4,"studyType":24,"phases":490,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":498,"leadSponsor":500,"locationsCount":47},"100632538","sirolimus-coated-vs-paclitaxel-coated-dcbs-in-acs-treatment-100632538","NCT07514988","Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment","Comparison Study of Sirolimus-Coated Versus Paclitaxel-Coated Coronary Drug-Coated Balloons in the Treatment of Acute Coronary Syndrome","Inclusion Criteria:\n\nSubjects must meet all of the following criteria to be enrolled:\n\n1. Age between 18 and 80 years old, both genders eligible;\n2. Coronary angiography showing non-complex lesions with acute coronary syndrome (non-ST-elevation myocardial infarction and unstable angina) deemed suitable for drug-coated balloon treatment by the investigator;\n3. Visually estimated lesion length ≤28mm, visually estimated vessel diameter ≥2.5mm and ≤3.0mm;\n4. Successful lesion pre-dilation (must simultaneously meet all 3 criteria: no Type C or greater dissection; TIMI flow grade 3; visually estimated residual stenosis ≤30%);\n5. Able to understand the study purpose, willing to complete follow-up visits, and voluntarily provide informed consent.\n\nExclusion Criteria:\n\nSubjects will be excluded if they meet any of the following criteria:\n\n1. Total occlusion (TIMI 0 flow) lesion;\n2. In-stent restenosis lesion;\n3. Concurrent left main disease or severe three-vessel disease requiring coronary artery bypass grafting;\n4. Target lesion with severe calcification or tortuosity that cannot be crossed by guidewire;\n5. Coronary artery bypass graft stenosis;\n6. Confirmed ST-elevation myocardial infarction;\n7. Cardiogenic shock or requiring mechanical respiratory and circulatory support;\n8. Hemodynamically unstable tachyarrhythmia or bradyarrhythmia;\n9. Severe renal insufficiency or undergoing hemodialysis;\n10. Known allergy or intolerance to aspirin, clopidogrel, ticagrelor, heparin, contrast media, paclitaxel, sirolimus and\u002For other analogues;\n11. Systemic lupus erythematosus or other systemic autoimmune diseases;\n12. History of stroke within 6 months prior to enrollment;\n13. Scheduled elective surgery within 6 months after enrollment requiring discontinuation of anticoagulant or antiplatelet medications;\n14. Currently participating in other drug or interventional medical device clinical studies;\n15. Other conditions deemed unsuitable for enrollment by the investigator.",{"count":489,"type":23},60,[26],"This study aims to investigate and compare the local inflammatory responses and plaque healing characteristics between sirolimus-coated and paclitaxel-coated coronary drug-coated balloons in patients with acute coronary syndrome.",[493],"Acute Coronary Syndromes (ACS)","2026-03-31",{"date":496,"type":39},"2026-04-07",{"date":290,"type":23},{"date":499,"type":23},"2028-07-01",{"name":45,"class":46},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":24,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":47},"100610689","a-study-evaluating-the-vascular-healing-and-neointimal-transformation-at-1-month-after-implantation-of-biofreedom-drug-coated-stents-and-the-xience-drug-eluting-stent-system-in-patients-with-acute-coronary-syndrome-and-high-bleeding-risk-using-optical-coherence-tomography-100610689","NCT07230847","A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Male or non-pregnant female\n3. Acute coronary syndrome (ACS) patients requiring percutaneous coronary intervention (PCI)\n4. No contraindications for coronary artery bypass grafting (CABG)\n5. High bleeding risk (HBR) patients per ARC-HBR definition (meeting ≥1 major or 2 minor criteria):\n\n   Major Criteria:\n   * Expected long-term oral anticoagulation\n   * Severe\u002Fend-stage chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin)\n   * Moderate\u002Fsevere anemia (Hb \\\u003C110 g\u002FL)\n   * Spontaneous bleeding requiring hospitalization\u002Ftransfusion within 6 months (or recurrent)\n   * Chronic bleeding diathesis\n   * Moderate\u002Fsevere thrombocytopenia pre-PCI (platelet count \\\u003C100×10⁹\u002FL)\n   * Liver cirrhosis with portal hypertension\n   * Active malignancy in past 12 months (excluding non-melanoma skin cancer; defined as diagnosis\u002Ftreatment within 12 months)\n   * History of spontaneous intracranial hemorrhage\n   * Traumatic intracranial hemorrhage within 12 months\n   * Known cerebral arteriovenous malformation\n   * Moderate\u002Fsevere ischemic stroke within 6 months\n   * Major surgery\u002Fsevere trauma within 30 days pre-PCI\n   * Planned non-deferrable major surgery during dual antiplatelet therapy\n\n   Minor Criteria:\n   * Age ≥75 years\n   * Moderate chronic kidney disease (eGFR:30\\~59 ml\u002Fmin)\n   * Mild anemia (male: Hb=110\\~129 g\u002FL; female: Hb=110\\~119 g\u002FL)\n   * Spontaneous bleeding requiring hospitalization\u002Ftransfusion within 6-12 months pre-PCI\n   * Chronic NSAID\u002Fsteroid use post-PCI\n   * Ischemic stroke \\>6 months pre-PCI\n6. Capable of understanding trial objectives and providing informed consent\n\nAngiographic Inclusion Criteria:\n\n1. Target lesion must be primary native coronary artery lesion\n2. Target lesion with ≥70% diameter stenosis (visual estimate), or 50-70% diameter stenosis (visual estimate) with ischemic evidence\n3. ≥1 non-target lesion requiring intervention\n4. Non-target lesions eligible for elective treatment within 1 month\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria:\n\n1. Presence of ≥1 evidence of heart failure including:\n\n   * NYHA Class III or higher, or\n   * Killip classification ≥ Grade 2, or\n   * Left ventricular ejection fraction (LVEF) ≤30% within 30 days pre-procedure (by echocardiography or intraoperative ventriculography)\n2. Cardiogenic shock patients\n3. Known allergies to: Aspirin \u002F clopidogrel \u002F ticagrelor \u002F heparin, Contrast agents\u002Fdrugs used in drug-eluting stents or contraindications to aspirin\u002F clopidogrel \u002F ticagrelor\n4. Life expectancy \\\u003C12 months or factors potentially compromising clinical follow-up\n5. Participation in other drug\u002Fmedical device trials prior to enrollment without reaching primary endpoint timelines\n6. History of substance abuse (alcohol\u002Fcocaine\u002Fheroin, etc.)\n7. Severe arrhythmias (e.g., high-risk ventricular premature contractions\u002F ventricular tachycardia)\n8. Other medical conditions deemed unsuitable by investigators\n\nAngiographic Exclusion Criteria:\n\n1. Left main coronary artery disease\n2. Bypass graft lesions\n3. Evidence of extensive thrombus in target vessel",{"count":489,"type":23},[26],"BioFreedom™ is the world's first polymer-free drug-coated stent (DCS), utilizing a proprietary microstructured surface technology. Its abluminal microporous surface directly carries BA9™ (a sirolimus derivative) with high lipophilicity. This design mitigates inflammatory responses while promoting early vascular healing and reducing thrombotic risk. Extensive clinical evidence has validated BioFreedom™'s superior performance in high-bleeding-risk (HBR) populations. However, comprehensive assessments of neointimal coverage and quantitative neointimal transformation post-implantation remain insufficient. With advancements in ultra-high-resolution optical coherence tomography (OCT), detailed evaluation of coronary stent healing has become feasible. This study will employ OCT to comparatively assess vascular healing patterns-including neointimal transformation and strut coverage-in ACS patients with HBR receiving either the commercially available BioFreedom™ DCS or Xience drug-eluting stent system. The findings will provide multidimensional insights into the devices' post-implantation efficacy and safety profiles.",[148,511],"Acute Coronary Syndrome",{"date":513,"type":39},"2026-04-06",{"date":515,"type":39},"2025-12-10",{"date":517,"type":23},"2027-03-31",{"name":45,"class":46},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":24,"phases":528,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":539,"locationsCount":83},"100621215","phase-2-ademetionine-in-obstructive-hypertrophic-cardiomyopathy-100621215","NCT07367724","Ademetionine in Obstructive Hypertrophic Cardiomyopathy","Safety and Efficacy of Ademetionine in Patients With Obstructive Hypertrophic Cardiomyopathy: A Multicenter, Double-Blind, Randomized Controlled, Phase 2 Study","Inclusion Criteria:\n\n* Meet the diagnostic criteria for HCM.\n* Age ≥ 18 years at screening.\n* LVEF ≥ 50% at screening.\n* Echocardiography demonstrates a resting or provoked LVOTG ≥ 30 mmHg at screening.\n* NYHA Functional Class II-III at screening.\n* Able to perform CPET.\n* Patients receiving treatment with β-blockers or non-dihydropyridine calcium channel blockers should have been on a stable dose for at least 6 weeks prior to randomization and are expected to maintain the same medication during the trial. Who have previously received cardiac myosin inhibitors (e.g., Mavacamten) must discontinue the treatment for at least 8 weeks prior to randomization.\n* Willing and able to sign the informed consent form and comply with all scheduled study visits.\n\nExclusion Criteria:\n\n* History of severe hypersensitivity to any component of Ademetionine 1,4-Butanedisulfonate Enteric-coated Tablets.\n* History of psychiatric disorders, or current use of antidepressants such as clomipramine.\n* Planned for any surgical (including septal reduction therapy) or interventional procedure during the trial period.\n* Planned use of cardiac myosin inhibitors (e.g., Mavacamten) during the trial period.\n* Currently pregnant or planning pregnancy.\n* Currently participation in another drug or device clinical trial.\n* History of any other disease with a life expectancy of less than 1 year.",{"count":527,"type":23},44,[529],"PHASE2","This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study will recruit patients with oHCM who, under double-blind conditions, will be randomly assigned to either the Ademetionine group or the placebo group. Follow-up visits will be conducted every 4 weeks until 16 weeks from baseline. After 16 weeks, the study will evaluating the effect of Ademetionine on exercise capacity, heart failure symptoms, cardiac structure and function, and quality of life, as well as safety and tolerability of Ademetionine in this patient population.",[532],"Obstructive Hypertrophic Cardiomyopathy (oHCM)","2026-03-18",{"date":535,"type":39},"2026-03-20",{"date":537,"type":39},"2026-01-01",{"date":111,"type":23},{"name":45,"class":46},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":548,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":47},"100558682","phase-1-a-study-on-the-efficacy-and-safety-of-empagliflozin-in-the-treatment-of-pulmonary-arterial-hypertension-100558682","NCT06554301","A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension","Inclusion Criteria:\n\n1. At least 18 years old.\n2. Sign the informed consent form.\n3. Subjects who are willing and able to comply with the requirements of prescribed visits, treatment plans, laboratory examinations and other research procedures.\n4. PAH with symptoms was initially diagnosed and belonged to one of the following subgroups:\n\n   A. Idiopathic pulmonary hypertension (IPAH); B. hereditary pulmonary hypertension (HPAH); C drug or toxin-induced PAH, based on previous exposure to drugs, chemicals or toxins, such as fenfluramine derivatives, other appetite suppressants, toxic rapeseed oil or L- tryptophan.\n\n   D. PAH is accompanied by:\n\n   A) connective tissue disease B) Congenital systemic-pulmonary shunt (surgical correction must be performed at least one year before screening, and there is no or no clinically insignificant systemic-pulmonary shunt \\[1.0≤ lung-systemic blood flow ratio (QP\u002FQS)≤1.5\\]), according to the opinion of the researcher.\n5. Received right heart catheterization (RHC) at the time of screening or within 5 years before screening (if RHC is not performed, it will be performed during screening), which is consistent with the diagnosis of PAH and meets all the following criteria:\n\n   A. mean pulmonary artery pressure (papm) \\> 20mmhg (at rest) B pulmonary arteriole wedge pressure (PAWP)≤15 mmHg (if reliable PAWP data cannot be obtained, left ventricular end diastolic pressure \\[LVEDP\\]≤15 mmHg).\n\n   C pulmonary vascular resistance (PVR) \\> 2.00 wood units (\\> 160 dynes\u002Fsec\u002Fcm5).\n6. There are symptoms of WHO\u002FNYHA FC Grade II or III.\n7. Stable PAH targeted background oral therapy. Subjects received endothelin receptor antagonist (ERA) and\u002For phosphodiesterase inhibitor type 5 (PDE5-I) or soluble guanylate cyclase (sGC) agonist. Stability was defined as no change in dose or regimen within 30 days before baseline and during the duration of the study.\n8. 6-minute walking distance (6 MWD) ≥ 150m.\n9. If the subject is taking concomitant drugs that can affect PAH (for example, calcium channel blockers, digoxin or L- arginine supplements), the dose must be kept stable for at least 30 days before the baseline visit and throughout the study.\n10. If there is the possibility of pregnancy, both male and female subjects should agree to use a highly effective contraceptive method during the whole study period (from informed consent to the end of follow-up).\n\nExclusion Criteria:\n\n* 1\\) Subjects shall not have the following three or more risk factors for left ventricular dysfunction: Body mass index (BMI)≥30 kg\u002Fm2 History of systemic hypertension\n\nThere is any of the following evidence to prove the history of major coronary artery disease:\n\nA coronary angiographic evidence of a history of myocardial infarction or percutaneous coronary intervention or coronary artery disease (at least one coronary artery stenosis \\> 50%); B. Positive results of exercise provocation test and image evidence; C. previous coronary artery bypass surgery; D. stable angina pectoris; 2) Pulmonary function tests (PFTs) conducted within 180 days before or during the screening showed mild or above lung diseases. Subjects who meet any of the following criteria will be excluded: A. forced expiratory volume in the first second (FEV1)\\<60% (expected value); or B total lung volume (TLC) \\< 60% of the estimated value. 3) The evidence of thromboembolic disease is confirmed by lung ventilation\u002Fperfusion (V\u002FQ) scanning or local standard diagnosis and treatment evaluation at the time of diagnosis or after diagnosis of PAH.\n\n4\\) Severe chronic liver disease (i.e. Child-pugh grade C), portal hypertension, cirrhosis or complications of cirrhosis\u002Fportal hypertension (e.g., history of varicose bleeding, history of hepatic encephalopathy).\n\n5\\) Confirm the active infection of hepatitis B virus (HBV) or hepatitis C virus (HCV).\n\n6\\) Subjects whose alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level is more than or equal to 3 times the normal upper limit value (ULN) or whose total bilirubin is more than or equal to 2 times ULN at the time of screening.\n\n7\\) Chronic renal insufficiency at screening, which is defined as serum creatinine \\> 2.5 mg\u002FdL or requiring dialysis support.\n\n8\\) Hemoglobin concentration \\< 9 g\u002FdL during screening. 9) diabetes. 10) cardiac function grade IV (NYHA classification) 11) The subject has been treated with IV or SC prostacyclin pathway drugs (for example, epoprostol, triprostinil or iloprost) at any time before baseline (allowed to be used in pulmonary vasodilation test).\n\n12\\) The subject has pulmonary vein occlusion disease. 13) Diagnosed and\u002For treated with malignant tumor within 5 years before screening, but excluding localized non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin, or radical resection of cervical carcinoma in situ.\n\n14\\) At the time of screening, there was a history of alcohol or drug abuse within 6 months.\n\n15\\) Start the exercise-based cardiopulmonary rehabilitation program within 90 days of the screening period and\u002For during the study period.\n\n16\\) Participated in other interventional clinical studies within 30 days before screening. It is allowed to participate in registered or observational studies at the same time, as long as the subjects meet all other selection criteria and comply with all research process requirements.\n\n17\\) Any reason (for example, any past or intermittent diseases) that the respondent thinks may increase the risk of participating in the study or may affect the study analysis and damage the study participation or collaboration, so that the subject cannot participate in the study.\n\n18\\) Those who are known to be allergic to Engelgin or any auxiliary materials. 19) According to the researcher\\'s judgment, life expectancy is less than 12 months.\n\n20\\) Pregnant or lactating women.",{"count":547,"type":23},72,[549],"PHASE1","The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin. The main questions it aims to answer are:\n\nBased on standard treatment, does empagliflozin reduce pulmonary artery pressure and improve cardiac function in patients with pulmonary arterial hypertension? What medical problems do participants have when taking empagliflozin? Researchers will compare empagliflozin to a placebo (a look-alike substance that contains no drug) to see if empagliflozin works to treat patients with pulmonary arterial hypertension.\n\nParticipants will:\n\nTake empagliflozin or a placebo every day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms and the drug taking situation",[74],"2026-03-17",{"date":554,"type":39},"2026-03-19",{"date":556,"type":39},"2024-10-20",{"date":558,"type":23},"2026-12",{"name":45,"class":46},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":409,"phases":4,"briefSummary":569,"conditions":570,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":47},"100630054","predicting-post-cardiac-surgery-acute-kidney-disease-a-machine-learning-approach-100630054","NCT07482683","Predicting Post-Cardiac Surgery Acute Kidney Disease: A Machine Learning Approach","Development and Validation of a Machine Learning-Based Risk Prediction Model for Acute Kidney Disease After Cardiac Surgery","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Undergoing coronary artery bypass grafting and\u002For heart valve surgery, with or without aortic surgery;\n* Baseline serum creatinine level \\\u003C 354 umol\u002FL;\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Emergency surgery;\n* Multiple surgeries or reoperation;\n* End-stage kidney disease (ESKD), renal replacement therapy, or kidney transplantation;\n* Occurrence of AKI within 1 week before surgery or unresolved AKI;\n* Death within 1 week after surgery.",{"count":568,"type":23},820,"Renal injury after cardiac surgery is one of the common complications with high incidence rate, high risk of death and progression to chronic kidney disease (CKD). Previous evaluations of perioperative renal function mainly focused on acute kidney injury (AKI) related to cardiac surgery within seven days after surgery. The newly proposed concept of acute kidney disease (AKD) in recent years refers to acute or subacute kidney injury lasting seven to ninety days. Research has found that AKD can occur after AKI or in patients without AKI, and the two are both related and independent of each other, possibly indicating different subtypes of kidney injury. AKD is not uncommon and is a more significant predictor of mortality and end-stage kidney disease (ESKD). Therefore, AKD may be an important window for identifying and managing high-risk patients after cardiac surgery. Due to limited research on AKD after cardiac surgery, the risk factors for AKD are currently unclear, and there are no clinically practical and effective risk stratification tools available. This study aims to establish a multimodal perioperative data platform through a retrospective cohort, and use machine learning methods to construct a risk prediction model for AKD after cardiac surgery. The accuracy and stability of the model will be validated in a prospective study cohort, and an online risk prediction and clinical decision-making tool will be developed to help clinicians quickly conduct personalized risk assessments and optimize diagnosis and treatment strategies, thereby improving patient prognosis and reducing medical costs.",[571],"Acute Kidney Disease","2026-03-15",{"date":554,"type":39},{"date":575,"type":23},"2026-03-01",{"date":577,"type":23},"2027-06-30",{"name":45,"class":46},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":409,"phases":4,"briefSummary":589,"conditions":590,"keywords":592,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":603,"locationsCount":47},"100629575","skeletal-muscle-multi-omics-analysis-and-risk-tailoring-in-sudden-cardiac-death-100629575","NCT07476456","Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death","Development and Implementation of an Artificial Intelligence-Driven Multimodal Skeletal Muscle Feature Fusion Model for Risk Prediction of Sudden Cardiac Death in Patients With Implantable Cardioverter-Defibrillators: The SMART-SCD Study.","SMART-SCD","Inclusion Criteria:\n\n* Undergoing first-time ICD implantation (including cardiac resynchronization therapy defibrillator, CRT-D implantation);\n* Completed multi-dimensional sarcopenia assessment at baseline;\n* Willing to receive prospective follow-up and signed the informed consent form (ICF)\n\nExclusion Criteria:\n\n* History of valvular heart disease (e.g., mitral stenosis, history of heart valve replacement or valvuloplasty, etc.);\n* Implanted ICD type is subcutaneous ICD (S-ICD) or extra-vascular ICD (EV-ICD);\n* Concomitant comorbidities affecting muscle metabolism, such as malignant tumors, severe liver or kidney disease, etc.",{"count":588,"type":23},421,"This study is designed as a prospective, single-center, observational cohort study (the SMART-SCD Study, full name: Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death), which enrolls high-risk populations meeting the criteria for implantable cardioverter defibrillator (ICD) implantation.\n\nThe research focuses on the mechanistic association between skeletal muscle metabolic disorders and ventricular arrhythmia (VA) as well as sudden cardiac death (SCD), and aims to construct a \"muscle-heart crosstalk\" risk early warning system through integration of multimodal skeletal muscle data. We will systematically collect the following data:\n\nBaseline handgrip strength measurement (Biomi-h500+X5); Functional diagnosis and phenotyping of sarcopenia conducted via the InBody 270 body composition analyzer; Non-contrast chest and abdominal computed tomography (CT) images (to extract novel imaging phenotypes including skeletal muscle density at the T12 vertebra level, intermuscular adipose tissue, subcutaneous adipose tissue, etc.); Serum biomarkers (GDF-8, Irisin, IL-6); Metabolomics data of skeletal muscle tissue from the ICD pocket (lipid\u002Fenergy metabolism profiles detected via the UPLC-QTOF\u002FMS platform); Ambulatory electrocardiographic data. All treatment and intervention regimens for patients will be independently formulated by clinicians in accordance with clinical guidelines, and the study itself does not involve any intervention measures. Prospective follow-up will be conducted at 3\u002F6\u002F12 months after ICD implantation. The primary endpoint is composite ventricular arrhythmia events (including SCD, appropriate ICD therapy documented by the device, and hemodynamically unstable ventricular tachycardia\u002Fventricular fibrillation), and the secondary endpoint is all-cause mortality.\n\nThrough the above prospective cohort study, we will integrate multimodal data including novel CT imaging phenotypes of skeletal muscle, metabolomics profiles and functional phenotyping of sarcopenia using artificial intelligence techniques, so as to construct a precision prediction model for SCD, screen novel CT imaging phenotypes of sarcopenia and myogenic metabolites, and finally establish a generalizable SCD risk assessment tool and individualized intervention strategies.",[591],"Sudden Cardiac Death",[593,594,595,596,597],"Sarcopenia","Skeletal Muscle Metabolism","Ventricular Arrhythmia","Multimodal Predictive Model","Sudden cardiac death","2026-03-12",{"date":552,"type":39},{"date":601,"type":23},"2026-03-16",{"date":478,"type":23},{"name":45,"class":46},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":433,"maxAge":612,"enrollmentInfo":613,"targetDuration":4,"studyType":24,"phases":614,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":47},"100624602","low-dose-colchicine-for-thromboprophylaxis-after-transcatheter-aortic-valve-replacement-100624602","NCT07411768","Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement","A Randomized Controlled Trial of Anti-Inflammatory Therapy to Reduce Transcatheter Heart Valve Thrombosis After Transfemoral Transcatheter Aortic Valve Replacement","LoDoCo-TAVR","Inclusion Criteria:\n\n* Patients with aortic stenosis aged 60-85 years.\n* Successful transfemoral TAVR (per VARC-3 criteria).\n* Voluntary participation with signed Informed Consent Form.\n\nExclusion Criteria:\n\n* Known hypersensitivity, allergy, or documented intolerance to colchicine.\n* Hematologic abnormalities defined as hemoglobin \\\u003C80 g\u002FL or white blood cell count \\\u003C4.0 × 10⁹\u002FL at screening.\n* Severe renal impairment defined as creatinine clearance \\\u003C30 mL\u002Fmin (calculated by the Cockcroft-Gault formula) or serum creatinine \\>2 × upper limit of normal (ULN).\n* Significant hepatic disease, including liver cirrhosis, chronic active hepatitis, hepatic injury (alanine aminotransferase \\>3 × ULN or total bilirubin \\>2 × ULN), or cholestasis.\n* Known history of bone marrow suppression.\n* Concomitant use of strong CYP3A4 or P-glycoprotein (P-gp) inhibitors, including but not limited to cyclosporine, amiodarone, clarithromycin, erythromycin, omeprazole, or verapamil.\n* Concomitant use of strong CYP3A4 or P-glycoprotein (P-gp) inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, or rifampin.\n* Known neuromuscular disorders or creatine kinase (CK) \\>3 × ULN at screening.\n* Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea.\n* Active malignancy or history of cancer.\n* Current use of systemic corticosteroids (oral or intravenous) or systemic immunosuppressive agents (topical or inhaled corticosteroids permitted).\n* Acute inflammatory condition or active viral infection at the time of enrollment.\n* Known galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n* Estimated life expectancy \\\u003C1 year as determined by the investigator.","85 Years",{"count":142,"type":23},[26],"This prospective, randomized, open-label study aims to evaluate the efficacy and safety of low-dose colchicine (0.5 mg daily) in reducing transcatheter heart valve (THV) thrombosis in patients after TAVR. Participants will be randomly assigned to either receive colchicine plus standard care or standard care alone for 12 months. The primary goal is to compare the rate of valve thrombosis between the two groups using 4D-CT imaging at one year. Additionally, the study will evaluate the treatment's impact on clinical outcomes and its overall safety profile.",[617,618,619],"Transcatheter Aortic Valve Replacement","Transcatheter Heart Valve Thrombosis","Anti-inflammatory Therapy","2026-03-11",{"date":598,"type":39},{"date":623,"type":23},"2026-03",{"date":625,"type":23},"2028-06",{"name":45,"class":46},{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":635,"targetDuration":4,"studyType":24,"phases":637,"briefSummary":638,"conditions":639,"keywords":641,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":647,"leadSponsor":648,"locationsCount":4},"100576602","phase-4-effects-of-nicorandil-on-microvascular-dysfunction-in-patients-with-stemi-undergoing-primary-pci-100576602","NCT06787430","Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI","Evaluating the Effects of Nicorandil on Microvascular Dysfunction in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","NORMAL","Inclusion Criteria:\n\n* Age between 18-80\n* Diagnosis of STEMI and indicating for primary PCI\n* Diagnostic coronary angiography showed definite culprit vessel and primary PCI was planned to treat the culprit vessel.\n* Reference vessel diameter of culprit vessel was greater than 2.0 mm\n* There was no flow-limiting stenosis for the non-culprit vessels.\n* Understand the aim of this trial and agree to sign the informed consent form.\n\nExclusion Criteria:\n\n* Acute in- stent thrombosis or in-stent stenosis lesions of culprit vessel.\n* Balloon angioplasty rather than stent was planned for the culprit vessel.\n* Allergic to nicorandil or systolic arterial pressure was less than 85mmHg before procedure\n* Vessel with twisted shape that was unable to be measured using AMR\n* Oral or intravenous use of nicorandil within one month.\n* Cardiac shock needing mechanical support.\n* Severely hepatic dysfunction.\n* Severely renal failure needing hemodialysis.\n* Contraindicated for coronary angiography or primary PCI.\n* Culprit vessels of left main or graft vessels.\n* Pregnant or nursing.\n* Others that investigators think should excluded.",{"count":636,"type":23},170,[144],"Despite the success of restoration of epicardial blood flow by the primary percutaneous coronary intervention (PPCI), approximately one half of patients with ST-segment elevation myocardial infarction (STEMI) have failed myocardial reperfusion, namely microvascular dysfunction. Previous studies have shown that coronary microvascular damage significantly impacts the prognosis of patients with STEMI. Therefore, restoration of microvascular function is quite important during the PPCI procedures. Recent clinical trials found that nicorandil, a hybrid ATP-sensitive potassium channel opening agent, improved microvascular function, prevented no-reflow phenomenon, and had beneficial cardioprotective effects in patients receiving PPCI. However, there was a lack of evidence on the protective effects of nicorandil on microvascular function. The coronary angiography-derived IMR (AMR) is a novel wire-free technology developed for fast computation of IMR in patients undergoing coronary angiography, thereby enabling the quantification of coronary microcirculation of patients. This study is aimed to investigate the effects of nicorandil on microvascular dysfunction as evaluated by AMR in patients with STEMI.",[640],"STEMI - ST-segment Elevation Myocardial Infarction",[642,643,644],"Nicorandil","STEMI","microvascular dysfunction",{"date":598,"type":39},{"date":575,"type":23},{"date":111,"type":23},{"name":45,"class":46},{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":4,"eligibilityCriteria":655,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":656,"targetDuration":4,"studyType":24,"phases":658,"briefSummary":659,"conditions":660,"keywords":663,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":673},"100520352","phase-4-effects-of-sglt2-inhibitors-in-pre-heart-failure-populations-with-hypertension-100520352","NCT06055452","Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension","Effects and Mechanism of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension","Inclusion Criteria:\n\n• Meeting all the following criteria:\n\n1. Aged 18 years and above.\n2. Hypertensive patients currently taking at least one antihypertensive medication as recommended by guidelines, and blood pressure is within the target range (\\\u003C140\u002F90 mmHg).\n3. Within 3 months prior to screening，result meet any of the following criteria:\n\n   1. Left atrial volume index \\> 34 mL\u002Fm² measured by echocardiography;\n   2. Average E\u002Fe' \\> 9 measured by echocardiography;\n   3. NT-proBNP \\> 125 ng\u002Fml.\n4. Signing an informed consent form.\n\nExclusion Criteria:\n\n* • Exclusion criteria include any of the following conditions:\n\n  1. History of diabetes.\n  2. History of heart failure.\n  3. History of myocardial infarction, acute coronary syndrome within the past 6 months, or planned coronary revascularization within the next 6 months\n  4. Left ventricular systolic dysfunction, defined as LVEF \\\u003C 50%.\n  5. Systolic blood pressure \\\u003C 100 mmHg.\n  6. A history of arrhythmias such as atrial fibrillation, atrial flutter, frequent atrial premature contractions, and frequent ventricular premature contractions may impact the structural and functional aspects of the heart.\n  7. Moderate and above valvular heart disease.\n  8. Severe obstructive disease of the left ventricular outflow tract, including aortic valve stenosis.\n  9. Confirmed diagnosis of cardiomyopathy and infiltrative myocardial diseases.\n  10. Visited within the past 1 month due to Genitourinary tract infection.\n  11. Chronic kidney disease or estimated Glomerular Filtration Rate (eGFR) \\\u003C 45 ml\u002Fmin\u002F1.73m².\n  12. Alanine aminotransferase or aspartate aminotransferase levels \\> 3 times the upper limit of normal.\n  13. Contraindications to taking SGLT2 inhibitors.\n  14. Currently taking SGLT2 inhibitors, SGLT-1\u002F2 inhibitors, or other antihyperglycemic medications (including metformin, glucagon-like peptide-1 receptor agonists, etc.).\n  15. Pregnancy or planning pregnant, or currently breastfeeding.\n  16. Malignant tumors or other severe illnesses with a life expectancy of less than 3 years.\n  17. History of alcohol abuse or substance abuse within the past year.\n  18. Mental disorders or communication barriers, cognitive impairments, or other severe illnesses that may affect participation in the study.\n  19. Participation in or currently participating in other clinical trials within the last 3 months.\n  20. Known poor compliance with study follow-up or study drug.\n  21. Any condition or contraindication that makes a person intolerant to magnetic resonance imaging (MRI) or contraindicates MRI examination, such as the presence of implanted intracranial aneurysm clips, cardiac pacemakers or defibrillators, insulin pumps, etc.",{"count":657,"type":23},120,[144],"In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg\u002Fd) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.",[661,662],"Pre-Heart Failure","Hypertension",[661,662,283,664],"Empagliflozin","2026-03-04",{"date":667,"type":39},"2026-03-05",{"date":669,"type":39},"2024-01-19",{"date":671,"type":23},"2026-12-31",{"name":45,"class":46},2,""]